MedPath

Phase 2 study of amrubicin in previously treated patients with malignant pleural mesothelioma

Not Applicable
Conditions
Malignant pleural mesothelioma
Registration Number
JPRN-UMIN000006381
Lead Sponsor
agasaki University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
32
Inclusion Criteria

Not provided

Exclusion Criteria

1.Symptomatic pericardial effusion 2.Symptomatic SVC syndrome required emergency radiation 3.Serious medical complications 4.Uncontrolled angina pectoris, myocardial infarction within 3 months, heart failure 5.Uncontrolled diabetes mellitus, hypertension, infection 6.Pulmonary fibrosis detectable on chest X ray films 7.Concomitant malignancy 8.Pregnant or milk-feeding female 9.Symptomatic brain metastasis 10.Other clinical difficulties to this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate
Secondary Outcome Measures
NameTimeMethod
Progression-free survival Overall survival safety
© Copyright 2025. All Rights Reserved by MedPath